Skip to content
Screener

Immunome IMNM Business Segments — Operating Expenses

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Operating Expenses
$100.15M-15.8%
Theravance Biopharma logo
TBPHSingle Reportable — Operating Expenses
$27.18M-8.9%
Dogwood Therapeutics logo
DWTXSingle Reportable — Operating Expenses
$5.08M+14.6%
SES AI logo
SESSingle Reportable — Operating Expenses
$19.08M-31.4%
Monarch Casino & Resort logo
MCRISingle Reportable — Operating Expenses
$110.07M+0.2%
Iovance Biotherapeutics, Inc. logo
IOVASingle Reportable — Operating Expenses
$103.03M-16.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.92B+221%
Enterprise value$2.35B+204%
P/S728.3×+656×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Immunome’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219425
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other direct research and development9,9714,673
Indirect research and development(2)16,31410,337
General and administrative(3)8,6497,376
Other segment expenses(4)8,5566,314
Total operating expenses59,33147,562
Loss from operations(59,331)(44,636)
Interest income5,4922,996
Net loss$(53,839)$(41,640)

Item 1. Financial Statements.

FAQ

What is Immunome's business segments — operating expenses?
Immunome (IMNM) reported business segments — operating expenses of -$59.33M in Q1 2026.
How has Immunome's business segments — operating expenses changed year-over-year?
Immunome's business segments — operating expenses decreased by 24.7% year-over-year, from -$47.56M to -$59.33M.
What is the long-term trend for Immunome's business segments — operating expenses?
Over 2 years (2023 to 2025), Immunome's business segments — operating expenses has grown at a 63.9% compound annual growth rate (CAGR), from $123.55M to $332.04M.
What does business segments — operating expenses mean?
The aggregate of all costs incurred to operate the business segment, including research and development, general and administrative, and other operational charges. This metric provides a comprehensive view of the total cash burn or resource consumption required to maintain the segment's activities. It is a key indicator of the company's overall operational scale and cost management discipline.

Ask your AI about Immunome's business segments — operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude